Novavax Inc (NVAX): Cash & Equivalents
$240.63M
As of 2025-12-31
$191.46M
As of 2026-06-30
-43.5%
3-year compound annual growth
-15.3%
5-year compound annual growth
+10.0%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $240.63M | -54.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $530.23M | -6.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $568.50M | -57.5% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $1.34B | -11.8% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $1.52B | +173.8% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $553.40M | +602.1% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $78.82M | +12.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $70.15M | -34.0% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $106.31M | -26.4% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $144.35M | +55.0% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $93.11M | +187.9% | 2018-03-14, Balance as of period end |
| 2014-12-31 | $32.34M | -72.9% | 2017-02-27, Balance as of period end |
| 2013-12-31 | $119.47M | +586.7% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $17.40M | +23.4% | 2015-02-27, Balance as of period end |
| 2011-12-31 | $14.10M | +75.0% | 2014-03-12, Balance as of period end |
| 2010-12-31 | $8.06M | -79.2% | 2013-03-12, Balance as of period end |
| 2009-12-31 | $38.76M | n/a | 2012-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
Compare NVAX, TECH, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗